BE1001204A5 - Utilisation de monoesters solubles dans l'eau d'acides gras comme solubilisants de medicaments. - Google Patents

Utilisation de monoesters solubles dans l'eau d'acides gras comme solubilisants de medicaments. Download PDF

Info

Publication number: BE1001204A5
Authority: BE; Belgium
Prior art keywords: pharmaceutical composition; water; cyclosporine; composition according; acid
Prior art date: 1987-09-15

Application number

BE8801044A

Other languages

English (en)

French (fr)

Original Assignee

Sandoz Sa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1987-09-15

Filing date

1988-09-12

Publication date

1989-08-16

1988-09-12 Application filed by Sandoz Sa filed Critical Sandoz Sa

1989-08-16 Application granted granted Critical

1989-08-16 Publication of BE1001204A5 publication Critical patent/BE1001204A5/fr

Links

XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 title claims abstract description 70
235000014113 dietary fatty acids Nutrition 0.000 title claims abstract description 31
229930195729 fatty acid Natural products 0.000 title claims abstract description 31
239000000194 fatty acid Substances 0.000 title claims abstract description 31
150000004665 fatty acids Chemical class 0.000 title claims abstract description 24
239000003814 drug Substances 0.000 title claims description 7
229940079593 drug Drugs 0.000 title description 4
230000003381 solubilizing effect Effects 0.000 title 1
229960001265 ciclosporin Drugs 0.000 claims abstract description 100
108010036949 Cyclosporine Proteins 0.000 claims abstract description 95
PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 claims abstract description 94
239000006104 solid solution Substances 0.000 claims abstract description 80
150000001875 compounds Chemical class 0.000 claims abstract description 33
108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 25
229920001184 polypeptide Polymers 0.000 claims abstract description 23
102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 23
150000003077 polyols Chemical class 0.000 claims abstract description 15
229920005862 polyol Polymers 0.000 claims abstract description 14
229920006395 saturated elastomer Polymers 0.000 claims abstract description 12
150000001720 carbohydrates Chemical class 0.000 claims abstract description 9
229930182912 cyclosporin Natural products 0.000 claims description 57
239000000243 solution Substances 0.000 claims description 49
239000008194 pharmaceutical composition Substances 0.000 claims description 41
239000002904 solvent Substances 0.000 claims description 41
239000000203 mixture Substances 0.000 claims description 25
KGUHOFWIXKIURA-VQXBOQCVSA-N [(2r,3s,4s,5r,6r)-6-[(2s,3s,4s,5r)-3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]oxy-3,4,5-trihydroxyoxan-2-yl]methyl dodecanoate Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](COC(=O)CCCCCCCCCCC)O[C@@H]1O[C@@]1(CO)[C@@H](O)[C@H](O)[C@@H](CO)O1 KGUHOFWIXKIURA-VQXBOQCVSA-N 0.000 claims description 23
229940032085 sucrose monolaurate Drugs 0.000 claims description 23
MUPFEKGTMRGPLJ-RMMQSMQOSA-N Raffinose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 MUPFEKGTMRGPLJ-RMMQSMQOSA-N 0.000 claims description 22
MUPFEKGTMRGPLJ-UHFFFAOYSA-N UNPD196149 Natural products OC1C(O)C(CO)OC1(CO)OC1C(O)C(O)C(O)C(COC2C(C(O)C(O)C(CO)O2)O)O1 MUPFEKGTMRGPLJ-UHFFFAOYSA-N 0.000 claims description 22
239000012736 aqueous medium Substances 0.000 claims description 22
MUPFEKGTMRGPLJ-ZQSKZDJDSA-N raffinose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)O1 MUPFEKGTMRGPLJ-ZQSKZDJDSA-N 0.000 claims description 22
239000006193 liquid solution Substances 0.000 claims description 20
239000013543 active substance Substances 0.000 claims description 18
229930006000 Sucrose Natural products 0.000 claims description 17
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 16
239000005720 sucrose Substances 0.000 claims description 16
238000001990 intravenous administration Methods 0.000 claims description 15
238000002360 preparation method Methods 0.000 claims description 15
239000000546 pharmaceutical excipient Substances 0.000 claims description 13
-1 ampoules Substances 0.000 claims description 12
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 9
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 7
IPCSVZSSVZVIGE-UHFFFAOYSA-N palmitic acid group Chemical group C(CCCCCCCCCCCCCCC)(=O)O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 claims description 7
ULQISTXYYBZJSJ-UHFFFAOYSA-N 12-hydroxyoctadecanoic acid Chemical compound CCCCCCC(O)CCCCCCCCCCC(O)=O ULQISTXYYBZJSJ-UHFFFAOYSA-N 0.000 claims description 6
239000002253 acid Substances 0.000 claims description 6
GHVNFZFCNZKVNT-UHFFFAOYSA-N decanoic acid Chemical compound CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 claims description 6
POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 claims description 6
FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 claims description 6
WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 claims description 6
239000002775 capsule Substances 0.000 claims description 4
239000003826 tablet Substances 0.000 claims description 4
WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 claims description 3
229940114072 12-hydroxystearic acid Drugs 0.000 claims description 3
LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 claims description 3
QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 claims description 3
239000005632 Capric acid (CAS 334-48-5) Substances 0.000 claims description 3
239000005635 Caprylic acid (CAS 124-07-2) Substances 0.000 claims description 3
239000005639 Lauric acid Substances 0.000 claims description 3
239000005642 Oleic acid Substances 0.000 claims description 3
ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 claims description 3
235000021314 Palmitic acid Nutrition 0.000 claims description 3
238000001816 cooling Methods 0.000 claims description 3
150000002016 disaccharides Chemical class 0.000 claims description 3
239000008187 granular material Substances 0.000 claims description 3
239000003018 immunosuppressive agent Substances 0.000 claims description 3
QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 claims description 3
238000002844 melting Methods 0.000 claims description 3
230000008018 melting Effects 0.000 claims description 3
WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 claims description 3
229960002446 octanoic acid Drugs 0.000 claims description 3
ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 claims description 3
229920001223 polyethylene glycol Polymers 0.000 claims description 3
WBHHMMIMDMUBKC-XLNAKTSKSA-N ricinelaidic acid Chemical compound CCCCCC[C@@H](O)C\C=C\CCCCCCCC(O)=O WBHHMMIMDMUBKC-XLNAKTSKSA-N 0.000 claims description 3
229960003656 ricinoleic acid Drugs 0.000 claims description 3
FEUQNCSVHBHROZ-UHFFFAOYSA-N ricinoleic acid Natural products CCCCCCC(O[Si](C)(C)C)CC=CCCCCCCCC(=O)OC FEUQNCSVHBHROZ-UHFFFAOYSA-N 0.000 claims description 3
239000000829 suppository Substances 0.000 claims description 3
TUNFSRHWOTWDNC-HKGQFRNVSA-N tetradecanoic acid Chemical compound CCCCCCCCCCCCC[14C](O)=O TUNFSRHWOTWDNC-HKGQFRNVSA-N 0.000 claims description 3
150000004043 trisaccharides Chemical class 0.000 claims description 3
230000003110 anti-inflammatory effect Effects 0.000 claims description 2
239000003096 antiparasitic agent Substances 0.000 claims description 2
229940125687 antiparasitic agent Drugs 0.000 claims description 2
239000000499 gel Substances 0.000 claims description 2
230000001506 immunosuppresive effect Effects 0.000 claims description 2
229940125721 immunosuppressive agent Drugs 0.000 claims description 2
238000004519 manufacturing process Methods 0.000 claims description 2
239000000155 melt Substances 0.000 claims description 2
235000021313 oleic acid Nutrition 0.000 claims description 2
238000007920 subcutaneous administration Methods 0.000 claims description 2
239000002202 Polyethylene glycol Substances 0.000 claims 2
229940033355 lauric acid Drugs 0.000 claims 2
229960002969 oleic acid Drugs 0.000 claims 2
239000002260 anti-inflammatory agent Substances 0.000 claims 1
229940121363 anti-inflammatory agent Drugs 0.000 claims 1
229940098695 palmitic acid Drugs 0.000 claims 1
125000000185 sucrose group Chemical group 0.000 claims 1
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 20
150000002148 esters Chemical class 0.000 description 16
229960004793 sucrose Drugs 0.000 description 15
108010036941 Cyclosporins Proteins 0.000 description 13
238000000034 method Methods 0.000 description 12
239000007864 aqueous solution Substances 0.000 description 10
JTIGKVIOEQASGT-UHFFFAOYSA-N proquazone Chemical compound N=1C(=O)N(C(C)C)C2=CC(C)=CC=C2C=1C1=CC=CC=C1 JTIGKVIOEQASGT-UHFFFAOYSA-N 0.000 description 10
229930105110 Cyclosporin A Natural products 0.000 description 9
229960002466 proquazone Drugs 0.000 description 9
239000007788 liquid Substances 0.000 description 8
239000000126 substance Substances 0.000 description 8
238000001802 infusion Methods 0.000 description 7
RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 6
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
238000010790 dilution Methods 0.000 description 6
239000012895 dilution Substances 0.000 description 6
239000007924 injection Substances 0.000 description 6
238000002347 injection Methods 0.000 description 6
239000006185 dispersion Substances 0.000 description 5
239000007791 liquid phase Substances 0.000 description 4
239000002244 precipitate Substances 0.000 description 4
239000007787 solid Substances 0.000 description 4
230000007928 solubilization Effects 0.000 description 4
238000005063 solubilization Methods 0.000 description 4
238000003756 stirring Methods 0.000 description 4
238000012360 testing method Methods 0.000 description 4
108010069514 Cyclic Peptides Proteins 0.000 description 3
102000001189 Cyclic Peptides Human genes 0.000 description 3
XZAGBDSOKNXTDT-UHFFFAOYSA-N Sucrose monopalmitate Chemical compound CCCCCCCCCCCCCCCC(O)=O.OC1C(O)C(CO)OC1(CO)OC1C(O)C(O)C(O)C(CO)O1 XZAGBDSOKNXTDT-UHFFFAOYSA-N 0.000 description 3
206010003246 arthritis Diseases 0.000 description 3
230000001363 autoimmune Effects 0.000 description 3
239000012141 concentrate Substances 0.000 description 3
238000004090 dissolution Methods 0.000 description 3
238000004108 freeze drying Methods 0.000 description 3
230000004968 inflammatory condition Effects 0.000 description 3
239000002245 particle Substances 0.000 description 3
239000000047 product Substances 0.000 description 3
229960003387 progesterone Drugs 0.000 description 3
239000000186 progesterone Substances 0.000 description 3
JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical class OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 2
GEUKOOCPPICVTB-SMOCYEBVSA-N (3s,6s,9s,12r,15s,18s,21s,24s,30s)-33-[(1r,2r)-1-hydroxy-2-methylhexyl]-1,4,7,10,12,15,19,25,28-nonamethyl-6,9,18,24-tetrakis(2-methylpropyl)-3,21,30-tri(propan-2-yl)-1,4,7,10,13,16,19,22,25,28,31-undecazacyclotritriacontane-2,5,8,11,14,17,20,23,26,29,32- Chemical compound CCCC[C@@H](C)[C@@H](O)C1N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C(=O)[C@H](C(C)C)NC1=O GEUKOOCPPICVTB-SMOCYEBVSA-N 0.000 description 2
208000023275 Autoimmune disease Diseases 0.000 description 2
FWKQNCXZGNBPFD-UHFFFAOYSA-N Guaiazulene Chemical compound CC(C)C1=CC=C(C)C2=CC=C(C)C2=C1 FWKQNCXZGNBPFD-UHFFFAOYSA-N 0.000 description 2
201000004681 Psoriasis Diseases 0.000 description 2
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
206010067584 Type 1 diabetes mellitus Diseases 0.000 description 2
239000000654 additive Substances 0.000 description 2
150000001408 amides Chemical group 0.000 description 2
150000001412 amines Chemical class 0.000 description 2
238000004458 analytical method Methods 0.000 description 2
230000000845 anti-microbial effect Effects 0.000 description 2
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 2
108010040781 dihydrocyclosporin D Proteins 0.000 description 2
201000010099 disease Diseases 0.000 description 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
239000010419 fine particle Substances 0.000 description 2
235000013305 food Nutrition 0.000 description 2
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
239000002609 medium Substances 0.000 description 2
150000004702 methyl esters Chemical class 0.000 description 2
238000002156 mixing Methods 0.000 description 2
239000004570 mortar (masonry) Substances 0.000 description 2
239000004006 olive oil Substances 0.000 description 2
235000008390 olive oil Nutrition 0.000 description 2
210000000056 organ Anatomy 0.000 description 2
229940124531 pharmaceutical excipient Drugs 0.000 description 2
230000000144 pharmacologic effect Effects 0.000 description 2
239000012071 phase Substances 0.000 description 2
230000036470 plasma concentration Effects 0.000 description 2
239000008389 polyethoxylated castor oil Substances 0.000 description 2
239000000843 powder Substances 0.000 description 2
229960004063 propylene glycol Drugs 0.000 description 2
238000011160 research Methods 0.000 description 2
210000003491 skin Anatomy 0.000 description 2
239000011780 sodium chloride Substances 0.000 description 2
ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 2
238000002560 therapeutic procedure Methods 0.000 description 2
102000003390 tumor necrosis factor Human genes 0.000 description 2
JTOKYIBTLUQVQV-QRVTZXGZSA-N (3s,6s,9s,12r,15s,18s,21s,24s,30s,33s)-30-[(1r)-1-hydroxyethyl]-33-[(e,1r,2r)-1-hydroxy-2-methylhex-4-enyl]-1,4,7,10,12,15,19,25,28-nonamethyl-6,9,18,24-tetrakis(2-methylpropyl)-3,21-di(propan-2-yl)-1,4,7,10,13,16,19,22,25,28,31-undecazacyclotritriacontan Chemical compound C\C=C\C[C@@H](C)[C@@H](O)[C@@H]1N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C(=O)[C@H]([C@@H](C)O)NC1=O JTOKYIBTLUQVQV-QRVTZXGZSA-N 0.000 description 1
QIZPVNNYFKFJAD-UHFFFAOYSA-N 1-chloro-2-prop-1-ynylbenzene Chemical compound CC#CC1=CC=CC=C1Cl QIZPVNNYFKFJAD-UHFFFAOYSA-N 0.000 description 1
OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
QWCKQJZIFLGMSD-UHFFFAOYSA-N 2-Aminobutanoic acid Natural products CCC(N)C(O)=O QWCKQJZIFLGMSD-UHFFFAOYSA-N 0.000 description 1
QEZGRWSAUJTDEZ-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]-3-(piperidine-1-carbonyl)pyrazol-1-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C=1C(=NN(C=1)CC(=O)N1CC2=C(CC1)NN=N2)C(=O)N1CCCCC1 QEZGRWSAUJTDEZ-UHFFFAOYSA-N 0.000 description 1
KSEBMYQBYZTDHS-UHFFFAOYSA-N 3-(4-hydroxy-3-methoxyphenyl)prop-2-enoic acid Chemical compound COC1=CC(C=CC(O)=O)=CC=C1O KSEBMYQBYZTDHS-UHFFFAOYSA-N 0.000 description 1
LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical class O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 1
206010002199 Anaphylactic shock Diseases 0.000 description 1
208000032467 Aplastic anaemia Diseases 0.000 description 1
208000023328 Basedow disease Diseases 0.000 description 1
241000282472 Canis lupus familiaris Species 0.000 description 1
206010008909 Chronic Hepatitis Diseases 0.000 description 1
241000223205 Coccidioides immitis Species 0.000 description 1
208000015943 Coeliac disease Diseases 0.000 description 1
206010009900 Colitis ulcerative Diseases 0.000 description 1
206010010741 Conjunctivitis Diseases 0.000 description 1
208000011231 Crohn disease Diseases 0.000 description 1
JTOKYIBTLUQVQV-UHFFFAOYSA-N Cyclosporin C Natural products CC=CCC(C)C(O)C1N(C)C(=O)C(C(C)C)N(C)C(=O)C(CC(C)C)N(C)C(=O)C(CC(C)C)N(C)C(=O)C(C)NC(=O)C(C)NC(=O)C(CC(C)C)N(C)C(=O)C(C(C)C)NC(=O)C(CC(C)C)N(C)C(=O)CN(C)C(=O)C(C(C)O)NC1=O JTOKYIBTLUQVQV-UHFFFAOYSA-N 0.000 description 1
QWCKQJZIFLGMSD-GSVOUGTGSA-N D-alpha-aminobutyric acid Chemical compound CC[C@@H](N)C(O)=O QWCKQJZIFLGMSD-GSVOUGTGSA-N 0.000 description 1
229930091371 Fructose Natural products 0.000 description 1
239000005715 Fructose Substances 0.000 description 1
RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
206010018364 Glomerulonephritis Diseases 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
206010072579 Granulomatosis with polyangiitis Diseases 0.000 description 1
208000015023 Graves' disease Diseases 0.000 description 1
208000023661 Haematological disease Diseases 0.000 description 1
206010019755 Hepatitis chronic active Diseases 0.000 description 1
206010021245 Idiopathic thrombocytopenic purpura Diseases 0.000 description 1
206010061218 Inflammation Diseases 0.000 description 1
108090001061 Insulin Proteins 0.000 description 1
102000004877 Insulin Human genes 0.000 description 1
208000029523 Interstitial Lung disease Diseases 0.000 description 1
ZCVMWBYGMWKGHF-UHFFFAOYSA-N Ketotifene Chemical compound C1CN(C)CCC1=C1C2=CC=CC=C2CC(=O)C2=C1C=CS2 ZCVMWBYGMWKGHF-UHFFFAOYSA-N 0.000 description 1
GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
206010029164 Nephrotic syndrome Diseases 0.000 description 1
208000030852 Parasitic disease Diseases 0.000 description 1
229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
206010036030 Polyarthritis Diseases 0.000 description 1
206010065159 Polychondritis Diseases 0.000 description 1
201000001263 Psoriatic Arthritis Diseases 0.000 description 1
208000036824 Psoriatic arthropathy Diseases 0.000 description 1
241000700159 Rattus Species 0.000 description 1
208000025747 Rheumatic disease Diseases 0.000 description 1
206010039710 Scleroderma Diseases 0.000 description 1
NWGKJDSIEKMTRX-AAZCQSIUSA-N Sorbitan monooleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O NWGKJDSIEKMTRX-AAZCQSIUSA-N 0.000 description 1
IYFATESGLOUGBX-YVNJGZBMSA-N Sorbitan monopalmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O IYFATESGLOUGBX-YVNJGZBMSA-N 0.000 description 1
235000021355 Stearic acid Nutrition 0.000 description 1
229940123445 Tricyclic antidepressant Drugs 0.000 description 1
201000006704 Ulcerative Colitis Diseases 0.000 description 1
206010046851 Uveitis Diseases 0.000 description 1
GCSPRLPXTPMSTL-IBDNADADSA-N [(2s,3r,4s,5s,6r)-2-[(2s,3s,4s,5r)-3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl] dodecanoate Chemical compound CCCCCCCCCCCC(=O)O[C@@]1([C@]2(CO)[C@H]([C@H](O)[C@@H](CO)O2)O)O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O GCSPRLPXTPMSTL-IBDNADADSA-N 0.000 description 1
ZFFCNTZCHDDATQ-UWFDMBNGSA-N [(2s,3r,4s,5s,6r)-2-[(2s,3s,4s,5r)-3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl] hexanoate Chemical compound CCCCCC(=O)O[C@@]1([C@]2(CO)[C@H]([C@H](O)[C@@H](CO)O2)O)O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O ZFFCNTZCHDDATQ-UWFDMBNGSA-N 0.000 description 1
239000004480 active ingredient Substances 0.000 description 1
230000000735 allogeneic effect Effects 0.000 description 1
239000003708 ampul Substances 0.000 description 1
208000003455 anaphylaxis Diseases 0.000 description 1
208000007502 anemia Diseases 0.000 description 1
229960004543 anhydrous citric acid Drugs 0.000 description 1
230000002141 anti-parasite Effects 0.000 description 1
230000000884 anti-protozoa Effects 0.000 description 1
239000004599 antimicrobial Substances 0.000 description 1
239000003904 antiprotozoal agent Substances 0.000 description 1
238000003556 assay Methods 0.000 description 1
201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 description 1
150000001545 azulenes Chemical class 0.000 description 1
150000001555 benzenes Chemical class 0.000 description 1
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
230000036765 blood level Effects 0.000 description 1
210000001185 bone marrow Anatomy 0.000 description 1
239000004359 castor oil Substances 0.000 description 1
235000019438 castor oil Nutrition 0.000 description 1
238000004587 chromatography analysis Methods 0.000 description 1
230000001684 chronic effect Effects 0.000 description 1
208000019425 cirrhosis of liver Diseases 0.000 description 1
201000003486 coccidioidomycosis Diseases 0.000 description 1
238000004440 column chromatography Methods 0.000 description 1
238000011970 concomitant therapy Methods 0.000 description 1
210000004087 cornea Anatomy 0.000 description 1
239000002537 cosmetic Substances 0.000 description 1
239000006071 cream Substances 0.000 description 1
125000004122 cyclic group Chemical group 0.000 description 1
108010019248 cyclosporin C Proteins 0.000 description 1
238000000354 decomposition reaction Methods 0.000 description 1
201000001981 dermatomyositis Diseases 0.000 description 1
230000001687 destabilization Effects 0.000 description 1
150000005690 diesters Chemical class 0.000 description 1
235000013681 dietary sucrose Nutrition 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
239000012153 distilled water Substances 0.000 description 1
238000009826 distribution Methods 0.000 description 1
125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
230000000694 effects Effects 0.000 description 1
239000007938 effervescent tablet Substances 0.000 description 1
230000002124 endocrine Effects 0.000 description 1
210000003743 erythrocyte Anatomy 0.000 description 1
150000002170 ethers Chemical class 0.000 description 1
238000001704 evaporation Methods 0.000 description 1
230000008020 evaporation Effects 0.000 description 1
125000005313 fatty acid group Chemical group 0.000 description 1
239000000945 filler Substances 0.000 description 1
238000011049 filling Methods 0.000 description 1
238000001914 filtration Methods 0.000 description 1
239000000796 flavoring agent Substances 0.000 description 1
235000013355 food flavoring agent Nutrition 0.000 description 1
230000037406 food intake Effects 0.000 description 1
210000001035 gastrointestinal tract Anatomy 0.000 description 1
239000007903 gelatin capsule Substances 0.000 description 1
239000008103 glucose Substances 0.000 description 1
ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
238000000227 grinding Methods 0.000 description 1
238000010438 heat treatment Methods 0.000 description 1
208000007475 hemolytic anemia Diseases 0.000 description 1
238000004128 high performance liquid chromatography Methods 0.000 description 1
230000003165 hydrotropic effect Effects 0.000 description 1
125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
208000016036 idiopathic nephrotic syndrome Diseases 0.000 description 1
229960003444 immunosuppressant agent Drugs 0.000 description 1
239000012535 impurity Substances 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
230000004054 inflammatory process Effects 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
229940125396 insulin Drugs 0.000 description 1
230000000968 intestinal effect Effects 0.000 description 1
238000011835 investigation Methods 0.000 description 1
239000000644 isotonic solution Substances 0.000 description 1
229960004958 ketotifen Drugs 0.000 description 1
210000003734 kidney Anatomy 0.000 description 1
208000017169 kidney disease Diseases 0.000 description 1
230000003902 lesion Effects 0.000 description 1
239000008297 liquid dosage form Substances 0.000 description 1
229940057995 liquid paraffin Drugs 0.000 description 1
210000004185 liver Anatomy 0.000 description 1
229940083747 low-ceiling diuretics xanthine derivative Drugs 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
210000004072 lung Anatomy 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
238000009115 maintenance therapy Methods 0.000 description 1
201000004792 malaria Diseases 0.000 description 1
LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
201000006417 multiple sclerosis Diseases 0.000 description 1
206010028417 myasthenia gravis Diseases 0.000 description 1
229940105132 myristate Drugs 0.000 description 1
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
239000002674 ointment Substances 0.000 description 1
210000003254 palate Anatomy 0.000 description 1
210000000496 pancreas Anatomy 0.000 description 1
239000002504 physiological saline solution Substances 0.000 description 1
208000030428 polyarticular arthritis Diseases 0.000 description 1
229920000728 polyester Polymers 0.000 description 1
238000001556 precipitation Methods 0.000 description 1
XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
229960004618 prednisone Drugs 0.000 description 1
102000004169 proteins and genes Human genes 0.000 description 1
108090000623 proteins and genes Proteins 0.000 description 1
206010039073 rheumatoid arthritis Diseases 0.000 description 1
201000000306 sarcoidosis Diseases 0.000 description 1
201000004409 schistosomiasis Diseases 0.000 description 1
238000007493 shaping process Methods 0.000 description 1
235000017557 sodium bicarbonate Nutrition 0.000 description 1
229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
239000008279 sol Substances 0.000 description 1
239000001570 sorbitan monopalmitate Substances 0.000 description 1
235000011071 sorbitan monopalmitate Nutrition 0.000 description 1
229940031953 sorbitan monopalmitate Drugs 0.000 description 1
229950004959 sorbitan oleate Drugs 0.000 description 1
230000006641 stabilisation Effects 0.000 description 1
238000011105 stabilization Methods 0.000 description 1
239000008117 stearic acid Substances 0.000 description 1
150000003431 steroids Chemical class 0.000 description 1
229940035023 sucrose monostearate Drugs 0.000 description 1
239000004094 surface-active agent Substances 0.000 description 1
201000000596 systemic lupus erythematosus Diseases 0.000 description 1
229960000278 theophylline Drugs 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
230000000699 topical effect Effects 0.000 description 1
239000003029 tricyclic antidepressant agent Substances 0.000 description 1
238000005199 ultracentrifugation Methods 0.000 description 1
238000002604 ultrasonography Methods 0.000 description 1
239000003981 vehicle Substances 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Oil, Petroleum & Natural Gas (AREA)
Bioinformatics & Cheminformatics (AREA)
Biochemistry (AREA)
Molecular Biology (AREA)
Dermatology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicinal Preparation (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

BE8801044A 1987-09-15 1988-09-12 Utilisation de monoesters solubles dans l'eau d'acides gras comme solubilisants de medicaments. BE1001204A5 (fr)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
DE3730909		1987-09-15
DE3802355		1988-01-27

Publications (1)

Publication Number	Publication Date
BE1001204A5 true BE1001204A5 (fr)	1989-08-16

Family

ID=25859774

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BE8801044A BE1001204A5 (fr)	1987-09-15	1988-09-12	Utilisation de monoesters solubles dans l'eau d'acides gras comme solubilisants de medicaments.

Country Status (24)

Country	Link
JP (1)	JP3090666B2 (da)
KR (1)	KR0131084B1 (da)
AT (1)	AT395819B (da)
AU (1)	AU628787B2 (da)
BE (1)	BE1001204A5 (da)
CA (1)	CA1338775C (da)
CH (1)	CH683672A5 (da)
DK (1)	DK175132B1 (da)
ES (1)	ES2012118A6 (da)
FI (1)	FI94837C (da)
FR (1)	FR2620336B1 (da)
GB (1)	GB2209671B (da)
GR (1)	GR1002243B (da)
HU (1)	HU205010B (da)
IE (1)	IE61195B1 (da)
IL (1)	IL87746A (da)
IT (1)	IT1224886B (da)
LU (1)	LU87335A1 (da)
MY (1)	MY103769A (da)
NL (1)	NL195094C (da)
NO (1)	NO179434C (da)
NZ (1)	NZ226163A (da)
PT (1)	PT88492B (da)
SE (1)	SE503279C2 (da)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6007840A (en) *	1988-09-16	1999-12-28	Novartis Ag	Pharmaceutical compositions comprising cyclosporins
KR0148748B1 (ko)	1988-09-16	1998-08-17	장 크라메르, 한스 루돌프 하우스	사이클로스포린을 함유하는 약학조성물
GR1000466B (el) *	1989-01-28	1992-07-30	Sandoz Ag	Μεθοδος παρασκευης νεων φαρμακευτικων μορφων κυκλοσπορινης.
CH679277A5 (da) *	1989-02-09	1992-01-31	Sandoz Ag
GB8916901D0 (en)	1989-07-24	1989-09-06	Sandoz Ltd	Improvements in or relating to organic compounds
US6262022B1 (en)	1992-06-25	2001-07-17	Novartis Ag	Pharmaceutical compositions containing cyclosporin as the active agent
HK1004520A1 (en)	1992-05-13	1998-11-27	Novartis Ag	Ophthalmic compositions containing a cyclosporin
PT589843E (pt)	1992-09-25	2002-04-29	Novartis Ag	Composicoes farmaceuticas contendo ciclosporinas
ATE398448T1 (de) *	1993-09-28	2008-07-15	Scherer Gmbh R P	Herstellung von weichgelatinekapseln
SK164796A3 (en)	1994-11-03	1997-06-04	Dresden Arzneimittel	Novel cyclosporine preparation forms for oral administration of and process for producing them
US5834017A (en) *	1995-08-25	1998-11-10	Sangstat Medical Corporation	Oral cyclopsporin formulations
US5827822A (en) *	1996-03-25	1998-10-27	Sangstat Medical Corporation	Cyclosporin a formulations as nanoparticles
US5766629A (en) *	1995-08-25	1998-06-16	Sangstat Medical Corporation	Oral cyclosporin formulations
US5962019A (en) *	1995-08-25	1999-10-05	Sangstat Medical Corporation	Oral cyclosporin formulations
DE19544507B4 (de)	1995-11-29	2007-11-15	Novartis Ag	Cyclosporin enthaltende Präparate
TW414696B (en) *	1996-07-01	2000-12-11	Mitsubishi Kagaku Foods Kk	Anti-bacteria agent
SK285019B6 (sk)	1997-01-30	2006-04-06	Novartis Ag	Tvrdá želatínová tobolka
GB2326337A (en) *	1997-06-20	1998-12-23	Phares Pharma Holland	Homogeneous lipid compositions for drug delivery
US7732404B2 (en)	1999-12-30	2010-06-08	Dexcel Ltd	Pro-nanodispersion for the delivery of cyclosporin
EP1558215A4 (en) *	2003-10-14	2007-09-12	Wockhardt Ltd	STERILE GELIFYING AGENTS
JP5422871B2 (ja) *	2006-10-24	2014-02-19	不二製油株式会社	イソフラボン類組成物

Citations (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR5986M (da) *	1966-11-22	1968-06-21
DE1617557A1 (de) *	1966-05-12	1971-04-01	Suga Kazuo	Stabile Oryzanolloesung und Verfahren zur Herstellung derselben
DE2241667B2 (de) *	1971-08-25	1974-09-19	Sumitomo Chemical Co., Ltd., Osaka (Japan)	Stabiles pharmazeutisches Mittel in Form einer wässrigen oralen anwendbaren Suspension
FR2381520A1 (fr) *	1977-02-28	1978-09-22	Yamanouchi Pharma Co Ltd	Compositions pour usage rectal
GB2015339A (en) *	1978-03-07	1979-09-12	Sandoz Ltd	Compositions comprising mono-cyclic peptides

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
NL284933A (da) *	1961-10-31
JPS57128634A (en) *	1981-02-03	1982-08-10	Eisai Co Ltd	Elastase-containing compound increasing absorption
EP0179583A1 (en) *	1984-10-04	1986-04-30	Merck & Co. Inc.	A system for enhancing the water dissolution rate and solubility of poorly soluble drugs
JPS61280435A (ja) *	1985-04-04	1986-12-11	Kanji Takada	サイクロスポリン類のリンパ指向性製剤

1988
- 1988-09-01 HU HU884518A patent/HU205010B/hu unknown
- 1988-09-12 CH CH3398/88A patent/CH683672A5/de not_active IP Right Cessation
- 1988-09-12 BE BE8801044A patent/BE1001204A5/fr not_active IP Right Cessation
- 1988-09-12 LU LU87335A patent/LU87335A1/xx unknown
- 1988-09-12 FR FR888811953A patent/FR2620336B1/fr not_active Expired - Lifetime
- 1988-09-13 IE IE277288A patent/IE61195B1/en not_active IP Right Cessation
- 1988-09-13 FI FI884192A patent/FI94837C/fi not_active IP Right Cessation
- 1988-09-13 PT PT88492A patent/PT88492B/pt not_active IP Right Cessation
- 1988-09-13 NO NO884052A patent/NO179434C/no not_active IP Right Cessation
- 1988-09-13 AU AU22172/88A patent/AU628787B2/en not_active Expired
- 1988-09-13 NZ NZ226163A patent/NZ226163A/xx unknown
- 1988-09-13 SE SE8803221A patent/SE503279C2/sv not_active IP Right Cessation
- 1988-09-13 CA CA000577214A patent/CA1338775C/en not_active Expired - Lifetime
- 1988-09-13 GB GB8821443A patent/GB2209671B/en not_active Expired - Lifetime
- 1988-09-14 IT IT8848349A patent/IT1224886B/it active
- 1988-09-14 IL IL87746A patent/IL87746A/xx active Protection Beyond IP Right Term
- 1988-09-14 MY MYPI88001027A patent/MY103769A/en unknown
- 1988-09-14 AT AT0224988A patent/AT395819B/de not_active IP Right Cessation
- 1988-09-14 GR GR880100602A patent/GR1002243B/el not_active IP Right Cessation
- 1988-09-14 DK DK198805111A patent/DK175132B1/da not_active IP Right Cessation
- 1988-09-14 KR KR1019880011874A patent/KR0131084B1/ko not_active Expired - Lifetime
- 1988-09-14 JP JP63231396A patent/JP3090666B2/ja not_active Expired - Lifetime
- 1988-09-15 ES ES8802831A patent/ES2012118A6/es not_active Expired - Lifetime
- 1988-09-15 NL NL8802275A patent/NL195094C/nl not_active IP Right Cessation

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE1617557A1 (de) *	1966-05-12	1971-04-01	Suga Kazuo	Stabile Oryzanolloesung und Verfahren zur Herstellung derselben
FR5986M (da) *	1966-11-22	1968-06-21
DE2241667B2 (de) *	1971-08-25	1974-09-19	Sumitomo Chemical Co., Ltd., Osaka (Japan)	Stabiles pharmazeutisches Mittel in Form einer wässrigen oralen anwendbaren Suspension
FR2381520A1 (fr) *	1977-02-28	1978-09-22	Yamanouchi Pharma Co Ltd	Compositions pour usage rectal
GB2015339A (en) *	1978-03-07	1979-09-12	Sandoz Ltd	Compositions comprising mono-cyclic peptides

Also Published As

Publication number	Publication date
FR2620336B1 (fr)	1991-10-25
CH683672A5 (de)	1994-04-29
KR890004694A (ko)	1989-05-09
KR0131084B1 (ko)	1998-04-17
NO884052L (no)	1989-03-16
DK511188A (da)	1989-03-16
FI94837B (fi)	1995-07-31
FI884192L (fi)	1989-03-16
SE8803221L (sv)	1989-03-16
NO179434C (no)	1996-10-09
SE503279C2 (sv)	1996-05-13
GB2209671A (en)	1989-05-24
NL8802275A (nl)	1989-04-03
PT88492B (pt)	1993-03-31
DK511188D0 (da)	1988-09-14
AT395819B (de)	1993-03-25
GR880100602A (el)	1989-06-22
IT1224886B (it)	1990-10-24
GR1002243B (en)	1996-04-22
MY103769A (en)	1993-09-30
AU2217288A (en)	1989-04-27
JP3090666B2 (ja)	2000-09-25
GB8821443D0 (en)	1988-10-12
PT88492A (pt)	1988-10-01
FI884192A0 (fi)	1988-09-13
FR2620336A1 (fr)	1989-03-17
ES2012118A6 (es)	1990-03-01
JPH01151526A (ja)	1989-06-14
LU87335A1 (fr)	1989-04-06
HUT49494A (en)	1989-10-30
IL87746A0 (en)	1989-02-28
CA1338775C (en)	1996-12-10
DK175132B1 (da)	2004-06-14
IT8848349A0 (it)	1988-09-14
IE882772L (en)	1989-03-15
ATA224988A (de)	1992-08-15
IE61195B1 (en)	1994-10-19
AU628787B2 (en)	1992-09-24
NO179434B (no)	1996-07-01
NL195094C (nl)	2003-12-17
SE8803221D0 (sv)	1988-09-13
GB2209671B (en)	1991-11-13
FI94837C (fi)	1995-11-10
IL87746A (en)	1992-07-15
NO884052D0 (no)	1988-09-13
HU205010B (en)	1992-03-30
NZ226163A (en)	1991-08-27

Legal Events

Date

Code

Title

Description

2008-09-30

RE20

Patent expired

Owner name: *NOVARTIS A.G.

Effective date: 20080912

Publication	Publication Date	Title
BE1001204A5 (fr)	1989-08-16	Utilisation de monoesters solubles dans l'eau d'acides gras comme solubilisants de medicaments.
US5756450A (en)	1998-05-26	Water soluble monoesters as solubilisers for pharmacologically active compounds and pharmaceutical excipients and novel cyclosporin galenic forms
BE1005236A3 (fr)	1993-06-08	Compositions pharmaceutiques a base de cyclosporines.
BE1010112A4 (fr)	1997-12-02	Compositions pharmaceutiques.
JP4073503B2 (ja)	2008-04-09	サイクロスポリンを含有する液体製剤とその調製方法
EP0593656B1 (fr)	1997-01-22	Nouvelles compositions a base de derives de la classe des taxanes
US5407683A (en)	1995-04-18	Pharmaceutical solutions and emulsions containing taxol
CN1121238C (zh)	2003-09-17	口服施用的具有简单组成和高生物利用度的环孢菌素新制剂形式及其制造方法
FR2642650A1 (fr)	1990-08-10	Nouvelles compositions pharmaceutiques a base de cyclosporines
FI89065C (fi)	1993-09-30	Foerfarande foer framstaellning av en ny siklosporin kristallform
FR2636534A1 (fr)	1990-03-23	Compositions pharmaceutiques a base de cyclosporines
HU201567B (en)	1990-11-28	Process for production of intravenous medical compositions containing cyclosphorin
LU86901A1 (fr)	1987-12-16	Compositions pharmaceutiques de polypeptides adaptees a la resorption gastro-intestinale
WO2002083178A1 (fr)	2002-10-24	Composition pharmaceutique a base de macrolides pour application locale en ophtalmologie
JP3917820B2 (ja)	2007-05-23	オザグレルナトリウム含有注射液およびその安定化方法
DE3830494B4 (de)	2006-05-18	Wasserlösliche Monoester als Solubilisatoren für pharmakologische Wirkstoffe und pharmazeutische Hilfsstoffe
KR0173349B1 (ko)	1999-02-01	사이클로스포린-함유 고체 분산체 조성물